Probable interaction between warfarin and rifaximin in a patient treated for small intestine bacterial overgrowth

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages

  Hoffman, Justin Thomas ^a,b   Hartig, Christine ^c   Sonbol, Eyman ^c,d   Lang, Megan ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b PFIZER INC   (United States)

^c UCSD MEDICAL CENTER   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Rifaximin; Small intestine bacterial overgrowth; Warfarin

Indexed keywords

CLONAZEPAM; CYTOCHROME P450 3A4; DOCUSATE SODIUM; ENSURE; ESCITALOPRAM; FLUTICASONE PROPIONATE PLUS SALMETEROL; HEMOGLOBIN; HYDROXYZINE; LANSOPRAZOLE; LUBIPROSTONE; RIFAXIMIN; SALBUTAMOL; SIMETHICONE; SUMATRIPTAN; WARFARIN; ZOLPIDEM;

ADULT; ARTICLE; BACTERIAL OVERGROWTH; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; EVENING DOSAGE; FEMALE; FLATULENCE; HUMAN; HYDROGEN BREATH TEST; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALNUTRITION; MIGRAINE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SMALL INTESTINE BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; TREATMENT DURATION; WHEEZING;

ANTICOAGULANTS; BACTERIAL INFECTIONS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINE, SMALL; MIDDLE AGED; RIFAMYCINS; WARFARIN;

EID: 79957563536     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P578     Document Type: Article

References (33)

1. Product information. Coumadin (warfarin). Princeton, NJ: Bristol-Myers Squibb Company, January 2009.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133:160-98. DOI 10.1378/chest.08-0670
3. Product information. Xifaxan (rifaximin). Morrisville, NC: Salix Pharmaceuticals, Inc., March 2008.
4. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66. DOI 10.1159/000081990
5. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(suppl 1):13-27. DOI 10.1159/000089776
6. Artsimovitch I, Vassylyeva MN, Svetlow D, et al. Allosteric modulation of the RNA polymerase catalytic reaction in an essential component of transcription control by rifamycins. Cell 2005;122:351-63.
7. Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 2007;27:1361-9.
8. Trapnell CB, Connolly M, Pentikis HS, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41: 222-8. DOI 10.1345/aph.1H395
9. Husebye E. The pathogenesis of gastrointestinal bacterial overgrowth. Chemotherapy 2005;51(suppl 1):1-22. DOI 10.1159/000081988
10. Di Steffano M, Miceli E, Missanelli A, Corazza GR. Treatment of small intestine bacterial overgrowth. Eur Rev Med Pharmacol Sci 2005;9:217-22.
11. Di Steffano M, Corazza GR. Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. Chemotherapy 2005;51(suppl 1):103-9. DOI 10.1159/000081996
12. Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988;16:312-6.
13. Di Steffano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short-term treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther 2000;14:551-6.
14. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin 1999;15:47-52.
15. Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-5. Epub 12 April 2005. DOI 10.1111/j.1365-2036.2005.02516.x
16. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25:781-6. DOI 10.1111/j.1365-2036.2007.03259.x
17. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007;333:266-70.
18. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-28.
19. Horn JR, Hansten PD, Chan L-N. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. DOI 10.1345/aph.1H423
20. Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother 2008;62:872-878. DOI 10.1093/jac/dkn330
21. Keung A, Reith K, Eller MG, Mckenzie KA, Cheng L, Weir SJ. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady state rifapentine pharmacokinetics: part I. Int J Tuberc Lung Dis 1999;3:426-36.
22. Li AP, Rieth MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine, and rifabutin. Chem Biol Interact 1997;107:17-30.
23. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet 2003;42:819-50. DOI 0312-5963/03/0009-0819/$30.00/0
24. Heimark LD, Gibaldi M, Trager WF, et al. The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987; 42:388-94.
25. O'Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 1975;83:506-8.
26. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Metabolism of cyclosporine A: IV purification of the rifampin-inducible human liver cytochrome P450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989;17:197-207.
27. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-53.
28. Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007;322:391-8.
29. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92.
30. Brufani M, Cellai L, Cerrini S, et al. X-ray crystal structure of 4-deoxy- 3'-bromopyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV. J Antibiot 1984; 37:1623-7.
31. Breen KJ, Bryant RE, Levinson JD, Schemker S. Neomycin absorption in man: studies of oral and enema administration and effect of intestinal ulceration. Ann Intern Med 1972;76:211-8.
32. Verardi S, Verardi V. Bile rifaximin concentration after oral administration in patients undergoing cholecystectomy. Farmaco 1990;45:131-5.
33. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87. DOI 10.1002/hep.22848